A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update

被引：0
|
作者：
Ahn, M-j.
Cho, B. C. [1 ]
Kim, T. M. [2 ]
Han, J-y.
Kim, C. [3 ]
Shim, B. [4 ]
Drilon, A. [5 ,6 ]
Blumenschein, G. [7 ]
Villaruz, L. [8 ]
Gray, J. E. [9 ]
Pujol, J-l. [10 ]
Lena, H. [11 ]
Moro-Sibilot, D. [12 ]
Perez, J. [13 ]
Modi, D. A. [13 ]
Park, J. S. [13 ]
Patel, S. [13 ]
Li, S. [13 ]
Kim, E. [13 ]
Magnan, H. [13 ]
机构：
[1] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[3] Georgetown Univ, Med Oncol, Hematol Oncol, Washington, DC USA
[4] Catholic Univ Korea, Dept Med Oncol, Seoul, South Korea
[5] Weill Cornell Med Ctr, Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[8] Univ Pittsburgh Med Ctr UPMC, Hillman Canc Ctr, Dept Oncol, Pittsburgh, PA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Tampa, FL USA
[10] Ctr Hosp Reg Univ CHRU Montpellier Arnaud Villeneu, Dept Thorac & Vasc Surg, Montpellier, France
[11] Univ Rennes, Dept Oncol, Rennes, France
[12] Ctr Hosp Univ Grenoble, F-38000 Grenoble, France
[13] Regeneron Pharmaceut Inc, Med Oncol, Tarrytown, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.754
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721TiP
引用
收藏
页码：S1673 / S1674
页数：2
相关论文
共 50 条
  • [11] A Phase I Trial of Sunitinib and Rapamycin in Patients with Advanced Non-Small Cell Lung Cancer
    Waqar, Saiama N.
    Gopalan, Priya K.
    Williams, Kristina
    Devarakonda, Siddhartha
    Govindan, Rarnaswamy
    CHEMOTHERAPY, 2013, 59 (01) : 8 - 13
  • [12] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer
    Evans, TRJ
    Mansi, JL
    Morgan, DAL
    Gyi, KM
    Banham, SW
    Milroy, R
    ONCOLOGY REPORTS, 1997, 4 (06) : 1337 - 1341
  • [13] A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer
    Waqar, Saiama N.
    Baggstrom, Maria Q.
    Morgensztern, Daniel
    Williams, Kristina
    Rigden, Caron
    Govindan, Ramaswamy
    CHEMOTHERAPY, 2015, 61 (03) : 144 - 147
  • [14] Telomerase peptide vaccination of patients with advanced non-small cell lung cancer - A phase I-II trial
    Brunsvig, P
    Gjertsen, M
    Kvalheim, G
    Sve, I
    Moller, M
    Eriksen, J
    Aamdal, S
    LUNG CANCER, 2005, 49 : S86 - S86
  • [15] Advanced non-small cell lung cancer (ANSCLC): New chemotherapy Phase II studies and old faults
    Tummarello, D
    Graziano, F
    LUNG CANCER, 1996, 15 (03) : 375 - 376
  • [16] A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer
    Hotta, K
    Sekine, I
    Tamura, T
    Sawada, M
    Watanabe, H
    Kusaba, H
    Akiyama, Y
    Inoue, A
    Shimoyama, T
    Nokihara, H
    Ueda, Y
    Yamamoto, N
    Kunitoh, H
    Ohe, Y
    Kodama, T
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (12) : 596 - 600
  • [17] Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study
    Masters, G
    ONCOLOGIST, 2001, 6 : 12 - 15
  • [18] A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Mikhaeel-Kamel, N
    Pan, ZX
    Murphy, J
    Prindiville, S
    Bunn, PA
    CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3474 - 3479
  • [19] Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer
    Ogawara, Daiki
    Nakamura, Yoichi
    Fukuda, Minoru
    Nakatomi, Katsumi
    Yamaguchi, Hiroyuki
    Motoshima, Kohei
    Mizoguchi, Kosuke
    Nakano, Hirofumi
    Takemoto, Shinnosuke
    Gyotoku, Hiroshi
    Nagashima, Seiji
    Kohno, Shigeru
    CHEMOTHERAPY, 2014, 60 (03) : 180 - 184
  • [20] A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Paik, P.
    Cortot, A.
    Felip, E.
    Sakai, H.
    Mazieres, J.
    Horn, L.
    Griesinger, F.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Veillon, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
12345